Skip to main content
Osnat Bartok on Muck Rack

Osnat Bartok

As seen in: Cell Press, Cell Reports, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Osnat

Contact Osnat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome

|
By Roberto Vendramin, Hongchang Fu, Shanila Fernandez Patel, Yue Zhao, Danwen Qian, Lorena Ligammari, Osnat Bartok, Polina Greenberg, Ronen Levy, Andrea Castro, Krupa Thakkar, Jun Murai, Wei-Ting Lu, Christopher C.T. Sng, Chen Weller, Gordon Beattie, Amandeep Bhamra, Roc Farriol-Duran, Despoina Karagianni, Krijn K. Dijkstra, Christopher L. Pinder, Benjamin Simpson, Gordon Cheung, Felipe Galvez-Cancino, Petra Vlckova, Silvia Surinova, Manuel Rodriguez-Justo, Mansi Shah, Nicholas McGranahan, Jeremy G. Carlton, Eva Grönroos, James L. Reading, Yardena Samuels, Charles Swanton, Sergio A Quezada, Kevin Litchfield, Marcellus Augustine
| Cell Press Verified
Keywords nonsense-mediated mRNA decay non-canonical neoantigens cryptic peptides cancer immunopeptidome SMG1 tumor immunogenicity cancer immunotherapy patient-derived fragments Introduction Effective anti-tumor immunity relies on the ability of T cells to detect cancer-associated peptides presented by the major histocompatibility complex (MHC) molecules and is shaped by both the quantity and quality of neoantigens.1,2 Among these, mutation-derived neoantigens (peptides derived from...
Open in Who Shared Issue with article?

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome

|
By Roberto Vendramin, Hongchang Fu, Shanila Fernandez Patel, Yue Zhao, Danwen Qian, Lorena Ligammari, Osnat Bartok, Polina Greenberg, Ronen Levy, Andrea Castro, Krupa Thakkar, Jun Murai, Wei-Ting Lu, Christopher C.T. Sng, Chen Weller, Gordon Beattie, Amandeep Bhamra, Roc Farriol-Duran, Despoina Karagianni, Marcellus Augustine, Krijn K. Dijkstra, Christopher L. Pinder, Benjamin Simpson, Gordon Cheung, Felipe Galvez-Cancino, Petra Vlckova, Silvia Surinova, Manuel Rodriguez-Justo, Mansi Shah, Nicholas McGranahan, Jeremy G. Carlton, Eva Grönroos, James L. Reading, Yardena Samuels, Charles Swanton, Sergio A Quezada, Kevin Litchfield
| Cell Press Verified
Keywords nonsense-mediated mRNA decay non-canonical neoantigens cryptic peptides cancer immunopeptidome SMG1 tumor immunogenicity cancer immunotherapy patient-derived fragments Introduction Effective anti-tumor immunity relies on the ability of T cells to detect cancer-associated peptides presented by the major histocompatibility complex (MHC) molecules and is shaped by both the quantity and quality of neoantigens.1,2 Among these, mutation-derived neoantigens (peptides derived from...
Open in Who Shared Issue with article?

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation

|
By Shira Sagie, Tomer Babu, Chen Weller, Ido Livneh, Nele P Quast, Nofar Gumpert, Alina S. Shomuradova, Ronen Levy, Dmitry Malko, Michal Alon, Franco Hessling Herrera, Mikhail Kutuzov, Mirie Zerbib, Polina Greenberg, Gil Benedek, Yishai Levin, Chani Stossel, Iris Kamer, Talia Golan, Roni Oren, Merav D. Shmueli, Osnat Bartok, Jair Bar, Jonathan Cohen, Omer Dushek, Charlotte M. Deane, Yardena Samuels, Claire Tabachnik, Matthew I. Raybould, Adi Alfia, Talal Ben Lulu, Talya Wasserman-Bartov
| Cell Reports Medicine Verified
Results Utilizing our previously developed data-driven pipeline,26 we prioritized candidate neoantigens from The Cancer Genome Atlas (TCGA) lung cancer dataset and identified the KRAS.G12V-HLA-A∗03:01 combination as a leading candidate. This HLA-mutation combination is found in approximately 94,000 patients worldwide (Figure 1A; Table S1).
Open in Who Shared Issue with article?
See all 7 articles